Pure Global

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight - Trial NCT06388187

Access comprehensive clinical trial information for NCT06388187 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06388187
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06388187
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity

Study Focus

Obesity

Cagrilintide

Interventional

drug

Sponsor & Location

Novo Nordisk A/S

Costa Mesa,Plantation,Indianapolis,Wilmington,Dallas,Arlington,Olympia,Surrey,Halifax,Hamilton,Pierre-Benite,Saint Herblain,Toulouse Cedex 9,Essen,Hamburg,Leipzig,Münster,Witten,Bradford-on-Avon,Brist, Canada,France,Germany,United Kingdom,United States of America

Timeline & Enrollment

Phase 3

Jun 24, 2024

Apr 10, 2026

300 participants

Primary Outcome

Relative change in body weight,Achievement of ≥5% weight reduction

Summary

This study will look at how well CagriSema helps people with excess body weight lose weight.
 CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and
 semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will
 either get CagriSema or dummy medicine and which treatment participant get is decided by
 chance. The study will last for about 1½ years for each participant.

ICD-10 Classifications

Obesity
Other obesity
Obesity, unspecified
Obesity due to excess calories
Obesity and other hyperalimentation

Data Source

ClinicalTrials.gov

NCT06388187

Non-Device Trial